DBCO-(PEG2-Val-Cit-PAB)2

DBCO-(PEG2-Val-Cit-PAB)2 Catalog number: BADC-01241

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Category
ADCs Linker
Product Name
DBCO-(PEG2-Val-Cit-PAB)2
Catalog Number
BADC-01241
Molecular Formula
C69H94N12O16
Molecular Weight
1347.56
Purity
>98.0%
DBCO-(PEG2-Val-Cit-PAB)2

Ordering Information

Catalog Number Size Price Quantity
BADC-01241 -- $-- Inquiry
Canonical SMILES
CC(C)C(C(=O)NC(CCCNC(=O)N)C(=O)NC1=CC=C(C=C1)CO)NC(=O)CCOCCOCCN(CCOCCOCCC(=O)NC(C(C)C)C(=O)NC(CCCNC(=O)N)C(=O)NC2=CC=C(C=C2)CO)C(=O)CCC(=O)N3CC4=CC=CC=C4C#CC5=CC=CC=C53
InChI
InChI=1S/C69H94N12O16/c1-46(2)62(66(90)76-55(14-9-31-72-68(70)92)64(88)74-53-23-17-48(44-82)18-24-53)78-58(84)29-35-94-39-41-96-37-33-80(60(86)27-28-61(87)81-43-52-13-6-5-11-50(52)21-22-51-12-7-8-16-57(51)81)34-38-97-42-40-95-36-30-59(85)79-63(47(3)4)67(91)77-56(15-10-32-73-69(71)93)65(89)75-54-25-19-49(45-83)20-26-54/h5-8,11-13,16-20,23-26,46-47,55-56,62-63,82-83H,9-10,14-15,27-45H2,1-4H3,(H,74,88)(H,75,89)(H,76,90)(H,77,91)(H,78,84)(H,79,85)(H3,70,72,92)(H3,71,73,93)/t55-,56-,62-,63-/m0/s1
InChIKey
OJIQRDAILYOKEI-MBSGQPJDSA-N
Solubility
10 mm in DMSO
Shelf Life
-20°C 3 years powder; -80°C 2 years in solvent
Shipping
-20°C (International: -20°C)
Storage
-20°C

DBCO-(PEG2-Val-Cit-PAB)2, a specialized chemical linker, plays a pivotal role in bioconjugation and drug delivery systems, particularly in the advancement of antibody-drug conjugates (ADCs). Here are four key applications of DBCO-(PEG2-Val-Cit-PAB)2:

Antibody-Drug Conjugates (ADCs): Positioned at the forefront of cancer therapy, this compound is indispensable for constructing ADCs that link potent cytotoxic drugs to specific antibodies targeting cancer cells. The PEG2 spacer adds bioavailability and flexibility, while the Val-Cit dipeptide responds to tumor-associated proteases to ensure drug release at the precise site. This meticulous delivery strategy heightens therapeutic efficacy and minimizes unintended impacts with surgical precision.

Bioconjugation: A cornerstone of bioconjugation endeavors, DBCO-(PEG2-Val-Cit-PAB)2 excels at labeling biomolecules such as proteins, peptides, and nucleic acids. The DBCO group interacts with azide-containing molecules through strain-promoted azide-alkyne cycloaddition (SPAAC), enabling efficient and enduring conjugation. This capability is crucial for crafting versatile bioconjugates utilized in diagnostics, imaging, and therapeutics across a diverse array of applications, pushing the boundaries of biotechnology.

Targeted Drug Delivery: Serving as a linchpin in the evolution of targeted drug delivery systems, this linker ensures the controlled release of therapeutic agents in response to specific triggers found in the tumor microenvironment. The PEG2-Val-Cit component guarantees stability during circulation and triggers drug release following enzymatic cleavage. Such precision drastically reduces systemic toxicity and amplifies the therapeutic potential of anticancer treatments.

Pharmaceutical Research: Within the intricate landscape of drug discovery and development, DBCO-(PEG2-Val-Cit-PAB)2 assumes a pivotal role in formulating dual-targeted or multifunctional drugs. Researchers leverage its capabilities to fuse disparate bioactive molecules, amalgamating therapeutic and diagnostic functionalities seamlessly. This adaptability cultivates the creation of cutting-edge therapies capable of diagnosing and treating diseases simultaneously, particularly within the dynamic realm of oncology.

1. Discovery of new ferroelectrics: [H2dbco]2 x [Cl3] x [CuCl3(H2O)2] x H2O (dbco = 1,4-Diaza-bicyclo[2.2.2]octane)
Wen Zhang, Heng-Yun Ye, Hong-Ling Cai, Jia-Zhen Ge, Ren-Gen Xiong, Songping D Huang J Am Chem Soc. 2010 Jun 2;132(21):7300-2.doi: 10.1021/ja102573h.
Compound [H(2)dbco](2) x [Cl(3)] x [CuCl(3)(H(2)O)(2)] x H(2)O undergoes a sharp dielectric anomaly and a paraelectric-to-ferroelectric phase transition at approximately -23 degrees C with a spontaneous polarization of 1.04 microC cm(-2), being the first molecular metal coordination compound ferroelectrics with a large dielectric response involving a 2 orders of magnitude enhancement and distinct Curie phase transition point. This work has proved an effective way for exploration of new ferroelectrics based on a five-coordinated divalent metal through the combination of crystal engineering and Landau phase transition theory.
2. Multi-antitumor therapy and synchronous imaging monitoring based on exosome
Ruijie Qian, Boping Jing, Dawei Jiang, Yongkang Gai, Ziyang Zhu, Xiaojuan Huang, Yu Gao, Xiaoli Lan, Rui An Eur J Nucl Med Mol Imaging. 2022 Jul;49(8):2668-2681.doi: 10.1007/s00259-022-05696-x.Epub 2022 Jan 29.
Background:Tumor-derived exosomes (TEX) have shown great potential for drug delivery and tumor targeting. Here, we developed a novel multi-drug loaded exosomes nanoprobe for combined antitumor chemotherapy and photodynamic therapy, and monitoring the drug delivery capabilities with pre-targeting technique.
3. Engineered DBCO+PD-1 Nanovesicles Carrying 1-MT for Cancer-Targeted Immunotherapy
Xichao Xu, Liang Liu, Huan Wang, Wenwen Li, Yigui Zou, Yinzhen Zeng, Qinghua Yang, Daming Bai, Dongling Dai ACS Biomater Sci Eng. 2022 Nov 14;8(11):4819-4826.doi: 10.1021/acsbiomaterials.2c00639.Epub 2022 Oct 7.
Liver cancer cells evade immune surveillance and anticancer response through various pathways, including the programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1) immune checkpoint axis that exhausts CD8+ T cells. Inhibitors or antibodies of the PD-L1/PD-1 signaling axis are considered promising drugs for cancer immunotherapy and exhibit favorable clinical responses. However, adverse effects, immune tolerance, and delivery barriers of most patients limit the clinical application of PD-L1/PD-1 antibodies. Thus, it is critical to develop a novel delivery strategy to enhance anticancer immunotherapy. In this study, we bioengineered cell membrane-derived nanovesicles (NVs) presenting PD-1 proteins and dibenzocyclooctyne (DBCO) to encapsulate 1-methyltryptophan (1-MT) (DBCO+PD-1@1-MT NVs). DBCO can specifically interact with N-azidoacetylmannosamine-tetraacetylate (Ac4ManN3) labeled onto metabolic cells for targeted killing of cancers. We next explored the effects of DBCO+PD-1@1-MT NVs on anticancer Hepa1-6 cells in vitro and in vivo. Results showed that PD-1@1-MT NVs dramatically inhibited Hepa1-6 proliferation, promoted peripheral blood mononuclear cell (PBMC) expansion, and strengthened anticancer therapy via blockading the PD-1/PD-L1 immune checkpoint axis, owing to the 1-methyltryptophan (1-MT) enhancement of anticancer immunotherapy efficacy through suppressing the activity of indoleamine 2,3-dioxygenase (IDO). Thus, 1-MT was encapsulated into PD-1 NVs to synergistically enhance cancer immunotherapy. Results have shown that PD-1@1-MT NVs obviously attenuated tumor growth, promoting IFN-γ production, increasing the T cells infiltration in tumors and spleens, and improving the survival period of tumor-bearing mice compared to monotherapy. Therefore, we propose a promising delivery strategy of the combination of DBCO+PD-1 NVs and 1-MT for specific and effective cancer-targeted immunotherapy.
The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Why Choose BOC Sciences?

Customer Support

Providing excellent 24/7 customer service and support

Project Management

Offering 100% high-quality services at all stages

Quality Assurance

Ensuring the quality and reliability of products or services

Global Delivery

Ensuring timely delivery of products worldwide

Questions & Comments
Verification code
Send Inquiry
Verification code
Resources & Supports
Inquiry Basket